Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamond BiofundTPE:6901 -3.93%16 14-Day RSI is 52.05 as of Jul. 18, 2026. GuruFocus rates TPE:6901 with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 1,705 Asset Management companies, Diamond Biofund ranks worse than 74.02% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-18), Diamond Biofund's 14-Day RSI is 52.05.
The industry rank for Diamond Biofund's 14-Day RSI or its related term are showing as below:
TPE:6901's 14-Day RSI is ranked worse than 74.02% of 1705
companies
in the Asset Management industry
Industry Median: 49.59
vs TPE:6901: 52.05
Diamond Biofund (TPE:6901) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Diamond Biofund 14-Day RSI Related Terms
TPE:6901 vs BLK, BX, KKR: 14-Day RSI Comparison
For the Asset Management subindustry, Diamond Biofund's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamond Biofund 14-Day RSI vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Diamond Biofund's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Diamond Biofund's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamond Biofund (TPE:6901) has a 14-Day RSI of 52.05 as of Jul. 18, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Diamond Biofund and its competitors. According to the industry distribution chart, Diamond Biofund ranks #1262 out of 1705 companies in the Asset Management industry, placing it in the top 74%.
Is Diamond Biofund's 14-Day RSI too high?
Diamond Biofund's current 14-Day RSI is 52.05. The Asset Management industry median 14-Day RSI is 49.59. Diamond Biofund's value of 52.05 is 5% above this industry median. Based on the distribution chart, Diamond Biofund ranks #1262 out of 1705 companies in the Asset Management industry, which is below the industry midpoint. Overall, Diamond Biofund has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's 14-Day RSI compare to BLK and BX?
According to the Asset Management industry distribution chart, Diamond Biofund ranks #1262 out of 1705 companies for 14-Day RSI. This places Diamond Biofund in the lower half of its industry. The industry median 14-Day RSI is 49.59. Diamond Biofund's value of 52.05 is 5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for an Asset Management company?
The median 14-Day RSI among Asset Management companies is 49.59, based on 1,705 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamond Biofund's current 14-Day RSI of 52.05 is 5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Diamond Biofund and its competitors. For the Asset Management industry, the median 14-Day RSI is 49.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamond Biofund's current 14-Day RSI is 52.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current 14-Day RSI of 52.05. The current 14-Day RSI is 52.05 and 5% above the Asset Management industry median of 49.59. Diamond Biofund's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current 14-Day RSI is 52.05 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
16GF Score
Get the complete analysis for TPE:6901
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6901 has been successfully added to your 
